Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer-Reference-Cited by-同舟云学术

Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer

Published:2011-10-05 Issue:11 Volume:118 Page:2787-2795
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Hartman Anne-Renee,Kaldate Rajesh R.,Sailer Lisa M.,Painter Lisa,Grier Charles E.,Endsley Robbin R.,Griffin Marlena,Hamilton Stephanie A.,Frye Cynthia A.,Silberman Mark A.,Wenstrup Richard J.,Sandbach John F.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference21 articles.

1. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes;Carey;Clin Cancer Res,2007

2. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer;Foulkes;J Natl Cancer Inst,2003

3. Molecular portraits of human breast tumours;Perou;Nature,2000

4. Repeated observation of breast tumor subtypes in independent gene expression data sets;Sorlie;Proc Natl Acad Sci U S A,2003

5. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer;Atchley;J Clin Oncol,2008

Cited by 171 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Empowerment, Pain Control, and Quality of Life Improvement in Early Triple-Negative Breast Cancer Patients through Pain Neuroscience Education: A Prospective Cohort Pilot Study Protocol (EMPOWER Trial);Journal of Personalized Medicine;2024-07-01

2. Small Molecule MIF Modulation Enhances Ferroptosis by Impairing DNA Repair Mechanisms;Advanced Science;2024-06-25

3. Characterization of HER2‐low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study;Cancer;2024-05-16

4. Long-term oncologic outcomes of unselected triple-negative breast cancer patients according to BRCA1/2 mutations;npj Precision Oncology;2024-04-30

5. A nano-cocktail of the PARP inhibitor talazoparib and CDK inhibitor dinaciclib for the treatment of triple negative breast cancer;Cancer Nanotechnology;2024-03-23